Rhenman & Partners Asset Management AB Boosts Position in Horizon Pharma PLC (HZNP)

Share on StockTwits

Rhenman & Partners Asset Management AB boosted its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 3.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 946,060 shares of the biopharmaceutical company’s stock after buying an additional 29,009 shares during the quarter. Horizon Pharma makes up approximately 2.1% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 15th largest holding. Rhenman & Partners Asset Management AB owned about 0.56% of Horizon Pharma worth $18,486,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Northern Trust Corp boosted its holdings in Horizon Pharma by 16.0% in the second quarter. Northern Trust Corp now owns 2,281,798 shares of the biopharmaceutical company’s stock worth $37,787,000 after purchasing an additional 314,156 shares in the last quarter. United Services Automobile Association boosted its holdings in Horizon Pharma by 11.0% in the second quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 2,679 shares in the last quarter. First Hawaiian Bank bought a new stake in Horizon Pharma during the third quarter valued at about $352,000. Nisa Investment Advisors LLC boosted its holdings in Horizon Pharma by 2,933.8% during the third quarter. Nisa Investment Advisors LLC now owns 21,995 shares of the biopharmaceutical company’s stock valued at $431,000 after acquiring an additional 21,270 shares during the period. Finally, Seven Eight Capital LP bought a new stake in Horizon Pharma during the third quarter valued at about $1,720,000. Institutional investors own 90.32% of the company’s stock.

A number of equities research analysts have issued reports on HZNP shares. Stifel Nicolaus upped their price target on shares of Horizon Pharma from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, November 1st. BidaskClub upgraded shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 5th. TheStreet upgraded shares of Horizon Pharma from a “c” rating to a “b-” rating in a report on Tuesday, November 20th. Mizuho restated a “buy” rating on shares of Horizon Pharma in a report on Tuesday, October 16th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Horizon Pharma in a report on Thursday, October 18th. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Horizon Pharma presently has a consensus rating of “Buy” and an average price target of $23.33.

Shares of HZNP opened at $22.90 on Monday. The stock has a market cap of $3.84 billion, a PE ratio of 19.41, a P/E/G ratio of 1.14 and a beta of 1.15. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.94 and a quick ratio of 1.86. Horizon Pharma PLC has a 52 week low of $12.55 and a 52 week high of $24.03.

In other news, EVP Geoffrey M. Curtis sold 8,835 shares of the company’s stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total transaction of $204,530.25. Following the completion of the transaction, the executive vice president now owns 32,202 shares of the company’s stock, valued at $745,476.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Timothy P. Walbert sold 408,347 shares of the company’s stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the transaction, the chairman now directly owns 650,404 shares of the company’s stock, valued at approximately $14,009,702.16. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by corporate insiders.

WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://weekherald.com/2019/02/11/rhenman-partners-asset-management-ab-boosts-position-in-horizon-pharma-plc-hznp.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Featured Article: Net Income

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply